-transparent.png){kind=logo}
The relative antineoplastic effectiveness of E. coli and Erwinia asparaginases was tested against lymphoid leukemias EARAD-1 and L5178Y/CA55. E. coli and Erwinia asparaginases had similar clearance rates from plasma in mice, and at a dose of 250 IU/kg body weight both enzymes lowered plasma asparagine to undetectable levels. Nevertheless, the dosage of Erwinia asparaginase needed to cause similar prolongation of median survival time in leukemic mice was at least twice that of E. coli asparaginase. The factors which may be responsible for the more potent therapeutic effectiveness of the E. coli asparaginase are discussed.
Related Publications
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
March 1971,
Journal of general microbiology,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
June 1974,
Cancer research,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
November 1975,
FEBS letters,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
September 2002,
FEBS letters,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
January 1970,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
July 2019,
Scientific reports,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
November 1966,
Proceedings of the National Academy of Sciences of the United States of America,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
March 1967,
Biochemistry,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
January 1977,
Izvestiia Akademii nauk SSSR. Seriia biologicheskaia,
J Roberts, and
F A Schmid, and
L J Old, and
E Stockert
May 1970,
Saishin igaku. Modern medicine,
